METI-DERM Drug Patent Profile
✉ Email this page to a colleague
When do Meti-derm patents expire, and what generic alternatives are available?
Meti-derm is a drug marketed by Schering and is included in one NDA.
The generic ingredient in METI-DERM is prednisolone. There are eighty-eight drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the prednisolone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Meti-derm
A generic version of METI-DERM was approved as prednisolone by ZHEJIANG XIANJU on May 2nd, 2024.
US Patents and Regulatory Information for METI-DERM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Schering | METI-DERM | prednisolone | CREAM;TOPICAL | 010209-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
